BPD, an AR ligand for prostate carcinoma targeting

Conclusion: The new compound BPD appears to be interesting tracer for use in the targeted radionuclide treatment of PC with AR overexpression and provides a good alternative to conventional PSMA ligands. It can be used in diagnosis as [68Ga]BPD as well as in therapy as [177Lu]BPD.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Schomaecker, K., Braun, F., Munoz Vazquez, S., Marmann, V., Fischer, T., Endepols, H., Freifrau von Brandenstein, M., Drzezga, A. Tags: Preclinical Probes for Oncology (Poster Session) Source Type: research